Transcutaneous delivery of therapeutic agents
AssigneeAlba Therapeutics Corporation
InventorsDorothea Sesardic, Blake Paterson
Life of this patent
Estimating the term…
Abstract
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
Claims16
A transcutaneous dosage composition comprising a therapeutic agent and a transcutaneous absorption enhancing amount of a tight junction agonist, wherein the tight junction agonist is a peptide comprising an amino acid sequence selected from the group consisting of:
- (a)
- (SEQ ID NO:
- 1)
- Phe Cys Ile Gly Arg Leu;
- (b)
- (SEQ ID NO:
- 2)
- Xaa1 Cys Ile Gly Arg Leu;
- (c)
- (SEQ ID NO:
- 3)
- Phe Xaa2 Ile Gly Arg Leu;
- (d)
- (SEQ ID NO:
- 4)
- Phe Cys Xaa3 Gly Arg Leu;
- (e)
- (SEQ ID NO:
- 5)
- Phe Cys Ile Xaa4 Arg Leu;
- (f)
- (SEQ ID NO:
- 6)
- Phe Cys Ile Gly Xaa5 Leu;
- (g)
- (SEQ ID NO:
- 7)
- Phe Cys Ile Gly Arg Xaa6;
- (h)
- (SEQ ID NO:
- 8)
- Xaa1 Xaa2 Ile Gly Arg Leu;
- (i)
- (SEQ ID NO:
- 9)
- Xaa1 Cys Xaa3 Gly Arg Leu;
- (j)
- (SEQ ID NO:
- 10)
- Xaa1 Cys Ile Xaa4 Arg Leu;
- (k)
- (SEQ ID NO:
- 11)
- Xaa1 Cys Ile Gly Xaa5 Leu;
- (l)
- (SEQ ID NO:
- 12)
- Xaa1 Cys Ile Gly Arg Xaa6;
- (m)
- (SEQ ID NO:
- 13)
- Phe Xaa2 Xaa3 Gly Arg Leu;
- (n)
- (SEQ ID NO:
- 14)
- Phe Xaa2 Ile Xaa4 Arg Leu;
- (o)
- (SEQ ID NO:
- 15)
- Phe Xaa2 Ile Gly Xaa5 Leu;
- (p)
- (SEQ ID NO:
- 16)
- Phe Xaa2 Ile Gly Arg Xaa6;
- (q)
- (SEQ ID NO:
- 17)
- Phe Cys Xaa3 Xaa4 Arg Leu;
- (r)
- (SEQ ID NO:
- 18)
- Phe Cys Xaa3 Gly Xaa5 Leu;
- (s)
- (SEQ ID NO:
- 19)
- Phe Cys Xaa3 Gly Arg Xaa6;
- (t)
- (SEQ ID NO:
- 20)
- Phe Cys Ile Xaa4 Xaa5 Leu;
- (u)
- (SEQ ID NO:
- 21)
- Phe Cys Ile Xaa4 Arg Xaa6;
- and
- (v)
- (SEQ ID NO:
- 22)
- Phe Cys Ile Gly Xaa5 Xaa6,
- wherein Xaa1 is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, Tyr, and Met;
- Xaa2 is selected from the group consisting of Gly, Ser, Thr, Tyr, Asn, and Gln;
- Xaa3 is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, and Met;
- Xaa4 is selected from the group consisting of Gly, Ser, Thr, Tyr, Asn, Ala, and Gln:
- Xaa5 is selected from the group consisting of Lys and His;
- Xaa6 is selected from the group consisting of Ala, Val, Leu, Ile, Pro, Trp, and Met.
Dependencies are inferred from the claim text.